Results 211 to 220 of about 5,563 (240)

Cardiovascular Toxicities Associated with Bispecific T-Cell Engagers

Blood, 2023
Background: Bispecific T-cell engagers (BTEs) are a novel class of drugs used to treat hematological malignancies that link endogenous tumor antigens to CD3 on the T-cell receptor, priming circulating T-cells to effectively target tumor cells.
Ahmed Sayed, Malak Munir, Sanam Ghazi, Mussammat Ferdousi, Satyam Krishan, Adnan Shaaban, Alma Habib, Onaopepo Kola-Kehinde, Patrick Ruz, Sarah Khan, Sneha Sharma, Alexa Mera, Narendranath Epperla, Daniel Addison   +13 more
openaire   +1 more source

Bispecific T-cell engager therapy for multiple myeloma

Best Practice & Research Clinical Haematology
With upfront use of triplet- and quadruplet-based regimens coupled with autologous stem cell transplant (ASCT) and maintenance lenalidomide, a high proportion of multiple myeloma (MM) patients are achieving deep and durable responses. Yet, myeloma invariably relapses, with refractoriness to one or more drugs at first relapse.
Diana Cirstea, Benjamin Puliafito, Bridget E. Kim, Matt Lei, Noopur Raje   +4 more
openaire   +2 more sources

The expanding success of T cell-engaging bispecific antibodies

Nature Cancer, 2023
openaire   +2 more sources

A PD-L1xCD3 bispecific nanobody as a novel T-cell engager in treating PD-L1 overexpression melanoma

Molecular Immunology, 2023
Baizhi Li, Baihui Shan, Fuqiu Li
exaly  

In situ subcutaneously injectable thermosensitive PEG-PLGA diblock and PLGA-PEG-PLGA triblock copolymer composite as sustained delivery of bispecific anti-CD3 scFv T-cell/anti-EGFR Fab Engager (BiTEE)

Biomaterials, 2021
Han Lin, Kuo-Hsiang Chuang, Ming-Thau Sheu   +2 more
exaly  

Characterization of an Anti-CD70 Half-Life Extended Bispecific T-Cell Engager (HLE-BiTE) and Associated On-Target Toxicity in Cynomolgus Monkeys

Toxicological Sciences, 2022
Tod A Harper, Lily Liu, Hervé Lebrec
exaly  

Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method

European Journal of Pharmaceutical Sciences, 2021
Junsheng Xue, Dongyang Liu
exaly  

T-cell engaging bispecific antibody therapy

2022
Patty A. Culp, Jeremiah D. Degenhardt, Danielle E. Dettling, Chad May   +3 more
openaire   +1 more source

Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody

Translational Oncology, 2021
Xianglei Liu, John W Mellors, Dimiter S Dimitrov   +2 more
exaly  

The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas

Cancers, 2023
Nicoletta Polerà, Antonia Mancuso, Katia Grillone   +2 more
exaly